Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Critical Reviews™ in Neurobiology

 

ISSN for PRINT: 0892-0915

Institutional price:

$649.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2004, Volume16

Issue 1&2

  194 pages  

DOI: 10.1615/CritRevNeurobiol.v16.i12   

click 'Save as...' here to save XML metadata

Issue price - $252.00  

Add to shopping cart

  • Peripheral Markers of Glutamatergic Dysfunction in Neurological Diseases: Focus on Ex Vivo Tools
  • Lucio Tremolizzo
    The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago Illinois, USA

    Simone Beretta
    Department of Neurology, S. Gerardo Hospital and Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy

    Carlo Ferrarese
    Department of Neurology, S. Gerardo Hospital and Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy


    ABSTRACT

    Since the proposal that excessive glutamatergic stimulation could be responsible for neuronal suffering and death, excitotoxicity and glutamate uptake deficits have been repeatedly confirmed to play a key role in the pathogenesis of different neurological diseases. Therefore, it is conceivable that assessing the glutamatergic system function directly in patients could be extremely useful for early diagnosis, prognostic evaluation, and optimization of the therapy. A possibility is offered by assessing glutamate levels in biological fluid, such as plasma and CSF, where increased levels of this amino acid have been reported in patients affected by stroke, amyotrophic lateral sclerosis (ALS), and AIDS dementia complex. However, the metabolic role of this amino acid acts as a confounding factor, and the possibility of directly assessing glutamatergic functional parameters, such as amino acid reuptake, would probably mirror closely the actual excitotoxic damage operative in each patient. Here we will describe our findings obtained in peripheral ex vivo cells, such as platelets and fibroblasts, both displaying a functional glutamate reuptake system. Consistent with a systemic-impairment assumption, glutamate uptake was shown to be reduced in peripheral cells of Alzheimer's disease, Down syndrome, Parkinson's disease, ALS, and stroke patients. Different systemic factors might be responsible for this phenomenon, including genetic predisposition, oxidative stress, and inflammatory response, raising new, exciting questions about the relevance of their possible interactions for the pathogenesis of neurological disorders.

    DOI: 10.1615/CritRevNeurobiol.v16.i12.150

    Download article, 141-146 pages

    Article price - $35.00  

    Add to shopping cart

    << Previous article   Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com